Abstract:Competitive bacteria-bacteriophage interactions have resulted in the evolution of a plethora of bacterial defense systems preventing phage propagation. In recent years, computational and bioinformatic approaches have underpinned the discovery of numerous novel bacterial defense systems. Anti-phage systems are frequently encoded together in genomic loci termed defense islands. Here we report the identification and characterisation of a novel anti-phage system, that we have termed Shield, which forms part of the Pseudomonas defensive arsenal. The Shield system comprises the core component ShdA, a membrane-bound protein harboring an RmuC domain. Heterologous production of ShdA alone is sufficient to mediate bacterial immunity against several phages. We demonstrate that Shield and ShdA confer population-level immunity and that they can also decrease transformation efficiency. We further show that ShdA homologues can degrade DNA in vitro and, when expressed in a heterologous host, can alter the organisation of the host chromosomal DNA. Use of comparative genomic approaches identified how Shield can be divided into four subtypes, three of which contain additional components that in some cases can negatively affect the activity of ShdA and/or provide additional lines of phage defense. Collectively, our results identify a new player within the Pseudomonas bacterial immunity arsenal that displays a novel mechanism of protection, and reveals a role for RmuC domains in phage defense. The evolutionary pressure exerted by bacteriophages has driven bacteria to acquire numerous defense systems. Recent studies have highlighted the extraordinary diversity of these systems, uncovering exciting links between bacterial and eukaryotic immunity. Here we describe a novel anti-phage system, named Shield, found within Pseudomonas species. We identify several Shield subtypes, all harboring the same core component, and describe its mode of action. The growing instance of multidrug-resistant bacterial infections urgently requires the development of alternative treatments. Phage therapy is a particularly pertinent approach to treat multi-drug resistant Pseudomonas aeruginosa strains causing severe lung infection in cystic fibrosis patients. A detailed understanding of bacterial immunity and phage counter-strategies is an essential step to underpin the rational design of phage therapy to fight disease.

Bacteria renew an OLD protein to cleave host tRNAs and block phage translation

Architecture and activation mechanism of the bacterial PARIS defence system

Architecture and infection-sensing mechanism of the bacterial PARIS defense system

A virally encoded tRNA neutralizes the PARIS antiviral defence system

Viral proteins activate PARIS-mediated tRNA degradation and viral tRNAs rescue infection

OLD family nuclease function across diverse anti-phage defense systems

Phages carry orphan antitoxin-like enzymes to neutralize the DarTG1 toxin-antitoxin defense system

Toxic anti-phage defense proteins inhibited by intragenic antitoxin proteins

An enterococcal phage protein broadly inhibits type IV restriction enzymes involved in antiphage defense

An enterococcal phage protein inhibits type IV restriction enzymes involved in antiphage defense

Anti-viral defense by an ADP-ribosyltransferase that targets mRNA to block translation

Structural and functional evidence of bacterial antiphage protection by Thoeris defense system via NAD+ degradation

Anti-viral defence by an mRNA ADP-ribosyltransferase that blocks translation

The DarTG toxin-antitoxin system provides phage defense by ADP-ribosylating viral DNA

The novel anti-phage system Shield co-opts an RmuC domain to mediate phage defense across Pseudomonas species

Structure-guided discovery of anti-CRISPR and anti-phage defense proteins

Phages reconstitute NAD to counter bacterial immunity

Retron-Eco1 assembles NAD + -hydrolyzing filaments that provide immunity against bacteriophages

Similar mechanisms of retron-mediated anti-phage defense for different families of tailed phages

Phage-triggered reverse transcription assembles a toxic repetitive gene from a noncoding RNA

Direct activation of a bacterial innate immune system by a viral capsid protein